Recent Advances, Bottlenecks, and Future Directions in

Gulbuse Turan, Maxence J Boggio, Ahmad Syibli Othman, Victory Nnaemeka, Adrian V S Hill, Ahmed M Salman

Abstract readReview

In one paragraph

Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gulbuse TuranJenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0009-0008-8092-1964

Maxence J BoggioJenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

Ahmad Syibli OthmanJenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-2020-900X

Victory NnaemekaJenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-3156-092X

Adrian V S HillJenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0003-0900-9629

Ahmed M SalmanJenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-9259-7339

Funding

Bill & Melinda Gates Foundation INV-006658

6 · The paper itself

Abstract

Malaria remains a major global health burden, with an estimated 282 million cases and 610,000 deaths reported in 2024, disproportionately affecting children under five years of age and pregnant women in sub-Saharan Africa. Although antimalarial drugs are highly effective at clearing infections, their reliance on timely diagnosis and treatment limits their scalability as a population-wide control strategy. Vaccines therefore represent a critical tool for reducing malaria-associated morbidity and mortality, as well as interrupting parasite transmission, by inducing durable protective immunity. However, the complex lifecycle of

Indexed as

global healthmalariaparasitesvaccinesvirus-like particles

Identifiers

PMID41893813

DOI10.3390/vaccines14030277

PMCPMC13030556

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.